• Shattuck Labs released Phase 1 results for SL-325, its DR3-blocking antibody, showing a clean safety profile with no major tolerability concerns.
• The study supported sustained target blockade, pointing to infrequent dosing potential, with limited immunogenicity risk seen in participants.
• A Phase 2b Crohn’s disease trial, RECEPTIVE-CD1, is slated to start in Q3 2026, with initial endoscopic results expected in H1 2028.
• Separately, the bispecific candidate SL-846 remains in IND-enabling toxicology, with safety and immunogenicity data expected in H2 2026.
• SL-846 is targeted for IND submission in H1 2027, with Phase 1 initiation planned for H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-263831), on June 09, 2026, and is solely responsible for the information contained therein.